Biocon Limited, a leading global biopharmaceutical company, recently announced a significant step in expanding access to its innovative diabetes treatment. Biocon signed an exclusive licensing and supply agreement with Biomm S.A., a prominent speciality pharmaceutical company in Brazil. This strategic partnership paves the way for the commercialisation of Semaglutide (gOzempic) in the Brazilian market, a …